IDH1 and glioblastoma: Despite our prognostic risk model being established in the previous GBM cohorts (IDH1 mutant and IDH1-WT), it showed a high performance in predicting the prognosis of GBM patients with IDH-WT that was redefined as GBM in the 2021 WHO classification of CNS tumors (Louis et al., 2021b).